TIDMMDC
RNS Number : 7016H
Mediclinic International plc
27 March 2020
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic" or "the Company" or "the Group")
27 March 2020
MEDICLINIC INTERNATIONAL PLC APPOINTS DAME INGA BEALE AS
INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHAIR DESIGNATE
Mediclinic, a leading international private healthcare services
group, announces the appointment of Dame Inga Beale as an
independent non-executive director and Chair Designate with effect
from 26 March 2020. Following a handover period, Dame Inga will
succeed Dr Edwin Hertzog as Chair upon his retirement at the
conclusion of the Company's annual general meeting on 22 July
2020.
Dame Inga has extensive business management and leadership
experience, and was appointed in 2014 as the first female Chief
Executive Officer of Lloyd's of London, the insurance and
reinsurance market, a position which she held until 2018. She
currently serves as an independent member of the global strategy
board of Clyde & Co LLP and as an independent non-executive
director on the boards of Crawford & Company and London First.
In addition, Dame Inga serves on the London Mayor's Business
Advisory Board. She is also Patron of Insuring Women's Futures and
Chair of the UK HIV Commission. During her executive career, she
held various senior leadership positions in Switzerland and
internationally across the insurance sector, including at
Converium, Zurich Insurance Group, Canopius and GE Insurance
Solutions.
Dame Inga is a Chartered Insurer and studied economics and
accounting. In 2017, she was appointed Dame Commander of the Order
of the British Empire for services to the UK economy.
Dame Inga has also been appointed as a member of the Nomination
Committee with effect from 26 March 2020.
Dr Edwin Hertzog, Chair of Mediclinic International,
commented:
"The Board is delighted to welcome Dame Inga as an independent
non-executive director and Chair Designate of the Company. She has
a clear understanding of our strong culture and values and will
also align readily with our business. Core to these matters are our
stakeholder commitment to deliver sustainable high-quality
healthcare services and our purpose to enhance the quality of life.
Dame Inga will expertly lead the Board in pursuit of these
objectives including the challenge if the COVID-19 pandemic
continues to spread globally."
Alan Grieve, the Company's Senior Independent Director, who led
the planned succession process, commented:
"I am very pleased with the outcome of the thorough and
independent process conducted to identify a successor to Dr
Hertzog. Dame Inga will contribute a wealth of business experience,
both as a leader and role model. During her tenure at Lloyd's of
London she initiated large-scale digital and cultural
transformation programmes and led its expansion into Dubai, China
and India. Dame Inga also played a critical role in advancing
diversity and inclusion initiatives across Lloyd's and the
international insurance sector."
Dame Inga Beale commented:
" I am very pleased to be joining Mediclinic International, an
organisation that puts patients at the heart of its business. The
Group has a clear strategy and exciting long-term outlook under the
leadership of Dr Ronnie Van der Merwe and his executive team. I
look forward to working with the Board, the executive team and
Mediclinic's various stakeholders as the Company builds on the
market-leading positions of its three divisions and adapts to the
changing global healthcare environment."
This announcement is made in accordance with the requirement of
LR 9.6.11. There are no further details that are required to be
disclosed under LR 9.6.13.
About Mediclinic International plc
Mediclinic is an international private healthcare services
group, established in South Africa in 1983, with divisions in
Switzerland, Southern Africa (South Africa and Namibia) and the
United Arab Emirates.
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for
all their healthcare needs.
Mediclinic is focused on providing specialist-orientated,
multi-disciplinary services across the continuum of care in such a
way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical
practitioners, funders and regulators of healthcare in each of its
markets.
As at 1 March 2020, Mediclinic comprised 77 hospitals, five
sub-acute hospitals, 14 day case clinics and 22 outpatient clinics.
Hirslanden operated 17 hospitals, two day case clinics and three
outpatient clinics in Switzerland with more than 1 800 inpatient
beds; Mediclinic Southern Africa operations included 53 hospitals
(three of which in Namibia), five sub-acute hospitals and 10 day
case clinics (four of which operated by Intercare) across South
Africa, and more than 8 500 inpatient beds; and Mediclinic Middle
East operated seven hospitals, two day case clinics and 19
outpatient clinics with more than 900 inpatient beds in the United
Arab Emirates.
The Company's primary listing is on the London Stock Exchange
("LSE") in the United Kingdom, with secondary listings on the JSE
Ltd ("JSE") in South Africa and the Namibian Stock Exchange ("NSX")
in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group
plc, a leading private healthcare group based in the United Kingdom
and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address : 6th Floor, 65 Gresham Street, London, EC2V
7NQ, United Kingdom
Website : www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International
plc and UBS Investment Bank
JSE sponsor : Rand Merchant Bank (A division of FirstRand Bank
Limited)
NSX sponsor : Simonis Storm Securities (Pty) Ltd
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAPPUGPWUPUGUQ
(END) Dow Jones Newswires
March 27, 2020 03:00 ET (07:00 GMT)
Mediclinic (LSE:MDC)
Historical Stock Chart
From Apr 2024 to May 2024
Mediclinic (LSE:MDC)
Historical Stock Chart
From May 2023 to May 2024